A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Current therapies for diffuse, intrinsic pontine glioma (DIPG) provide very limited benefit
to the patient. The rationale for the use of Antineoplaston therapy in this protocol study
derives from experience with subjects from prior Phase 2 studies and Compassionate Exemption
patients treated with Antineoplaston therapy at the Burzynski Clinic.
This study is designed to analyze the efficacy and safety of Antineoplaston therapy in five
separate DIPG patient cohorts, which are defined by age and prior therapy. This is a two
stage study with 20 patients in each cohort being enrolled in the first stage and an
additional 20 patients being enrolled in the second stage, if pre-determined efficacy
endpoints in the first stage are realized.